Aclarion, Inc. has published its 2026 Shareholder Letter, detailing the company’s clinical and financial strategies as it progresses through its clinical trial for treating chronic low back pain. Aclarion expects an internal readout of the 300-patient CLARITY trial by the end of Q3 and plans to publicly disclose preliminary results in Q4 of 2026.
The Broomfield-based company has reported a strengthened financial position, with sufficient cash to support operations through 2028 and a commitment to avoid new capital raises until after the trial results are disclosed. “Aclarion enters 2026 with a strengthened balance sheet, a scalable software-native business model, and a clear path to an initial readout on our CLARITY trial,” said Jeff Thramann, Executive Chairman of Aclarion.
Aclarion does not have an existing at-the-market (ATM) program and allowed its equity line of credit (ELOC) to expire at the end of 2025. The company will not pursue a new ATM or ELOC until after it reports its trial results.
In 2026, Aclarion plans to focus on raising awareness among institutional healthcare investors and improving its visibility in the medical and financial media.
The primary source was GlobeNewswire.